Researchers have developed a treatment combining two medicines, Trodelvy and Keytruda, which significantly reduced the risk of tumor progression in women with aggressive breast cancer. The Phase 3 study’s results could lead to a new treatment option for patients with triple-negative breast cancer, offering hope for improved outcomes.
Source: https://www.statnews.com/2025/05/31/trodelvy-keytruda-breast-cancer-gilead-merck-results